Jiangsu Hengrui Pharma's oral thrombopoietin (TPO) receptor agonist hetrombopag has been approved in China to treat low ...

Plump is due to step down in June 2027. Until then, he will continue in the role of president of R&D – and remain a member of ...

AbbVie's Qulipta has become the first oral CGRP inhibitor to show efficacy in a phase 3 study involving women with menstrual ...

The National Commission into the Regulation of AI in Healthcare has delivered its keenly anticipated report, which gives ...

Right after reporting encouraging data with its Dravet syndrome gene therapy, Encoded Therapeutics has raised an impressive ...

Some pharmacists in England can now prescribe medicines for acne, migraines, scabies, ear infections, and rhinitis in a major expansion of the Pharmacy First scheme first introduced in 2024. The five ...

Susan Marlin, chief executive of Clinical Trials Ontario, and Invest Ontario's life sciences lead Garrett Tone, say changes ...

Europe is rapidly becoming a hub for next-generation CNS biomarker innovation, with advances in blood-based, digital and ...

The FDA has just started a priority review of Roche's anti-IL-6 inhibitor Enspryng (satralizumab) for MOGAD – myelin ...

Bayer has won FDA approval for oral HER2 inhibitor Hyrnuo as a first-line treatment for advanced HER2-mutant non-small cell ...

Now We Must", this year emphasised the urgency and possibility of ending malaria with existing tools, progressive science, ...

Gilead's twice-yearly injectable for pre-exposure prophylaxis (PrEP) of HIV, lenacapavir, will not be routinely funded by the ...